Exchange of extracellular domains of CCR1 and CCR5 reveals confined functions in CCL5-mediated cell recruitment

Thrombosis and Haemostasis

Volumn 110, Issue 4, 2013, Pages 795-806

  Kramp, Birgit K ^a   Megens, Remco T A ^a,c   Sarabi, Alisina ^b   Winkler, Sabine ^b   Projahn, Delia ^b   Weber, Christian ^a,c,d   Koenen, Rory R ^a,c   von Hundelshausen, Philipp ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Arrest; Chemokine receptor chimera; Chemotaxis; Inflammation; RANTES

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; PROTEOGLYCAN; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; CHEMOTAXIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISULFIDE BOND; ENDOTHELIUM CELL; ENZYME LOCALIZATION; FLOW CYTOMETRY; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MICROENVIRONMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS;

ARREST; CHEMOKINE RECEPTOR CHIMERA; CHEMOTAXIS; INFLAMMATION; RANTES;

ANIMALS; CELL MOVEMENT; CHEMOKINE CCL5; DIMERIZATION; DNA SHUFFLING; HEK293 CELLS; HUMANS; MICE; MUTATION; PLATELET FACTOR 4; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CCR5; TRANSGENES;

EID: 84884888466     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0420     Document Type: Article

References (36)

1. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
2. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
4. Blanchet X, Langer M, Weber C, et al. Touch of chemokines. Frontiers Immunol 2012; 3: 175.
5. Blanpain C, Migeotte I, Lee B, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999; 94: 1899-1905.
6. Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011; 11: 355-363.
7. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
8. Baltus T, Weber KS, Johnson Z, et al. Oligomerisation of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 2003; 102: 1985-1988.
9. Weber C, Weber KS, Klier C, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 2001; 97: 1144-1146.
10. Czaplewski LG, McKeating J, Craven CJ, et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterisation of active disaggregated chemokine variants. J Biol Chem 1999; 274: 16077-16084.
11. Martin L, Blanpain C, Garnier P, et al. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001; 40: 6303-6318.
12. Proudfoot AE, Fritchley S, Borlat F, et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001; 276: 10620-10626.
13. Segerer S, Djafarzadeh R, Grone HJ, et al. Selective binding and presentation of CCL5 by discrete tissue microenvironments during renal inflammation. J Am Soc Nephrol 2007; 18: 1835-1844.
14. Segerer S, Johnson Z, Rek A, et al. The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. Mol Immunol 2009; 46: 2533-2538.
15. Johnson Z, Kosco-Vilbois MH, Herren S, et al. Interference with heparin binding and oligomerisation creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 2004; 173: 5776-5785.
16. Braunersreuther V, Steffens S, Arnaud C, et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008; 28: 1090-1096.
17. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
18. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
19. Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database 2011; 2011: bar009.
20. Thompson JD, Higgins DG, Gibson TJ, Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
21. Sarabi A, Kramp BK, Drechsler M, et al. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment. J Thromb Haemost 2011; 9: 209-219.
22. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerisation are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1890.
23. Vasina EM, Cauwenberghs S, Feijge MA, et al. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis 2011; 2: e211.
24. Thiele S, Steen A, Jensen PC, et al. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 2011; 286: 37543-37554.
25. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330: 1066-1071.
26. Grommes J, Alard JE, Drechsler M, et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med 2012; 185: 628-636.
27. Kramp BK, Sarabi A, Koenen RR, et al. Heterophilic chemokine receptor interactions in chemokine signalling and biology. Exp Cell Res 2011; 317: 655-663.
28. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et al. Chemokine receptor homoor heterodimerisation activates distinct signalling pathways. Embo J 2001; 20: 2497-2507.
29. Wright WR, Parzych K, Crawford D, et al. Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLoS One 2012; 7: e30120.
30. Ren M, Guo Q, Guo L, et al. Polymerisation of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J 2010; 29: 3952-3966.
31. Kenakin T. Functional selectivity and biased receptor signalling. J Pharmacol Exp Therap 2011; 336: 296-302.
32. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
33. Furuichi K, Gao JL, Horuk R, et al. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol 2008; 181: 8670-8676.
34. Horuk R, Shurey S, Ng HP, et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 2001; 76: 193-201.
35. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009; 8: 23-33.
36. Bedke J, Kiss E, Schaefer L, et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007; 7: 527-537.